Alpha Tau Medical (DRTS) director discloses shares, RSUs and options
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Alpha Tau Medical Ltd. director Blumenfeld S. Morry filed an initial Form 3 reporting his existing equity position. He directly holds 155,771 Ordinary Shares of Alpha Tau Medical and 4,680 Restricted Share Units, which will vest in full on the earlier of one year from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to his continued service.
He also reports multiple option grants over Ordinary Shares at exercise prices ranging from $2.98 to $11.50 per share, with expirations between 2028 and 2036. Footnotes indicate that some options are already fully vested, while others will vest in their entirety on the same schedule tied to March 9, 2026 or the next Annual General Meeting.
Positive
- None.
Negative
- None.
Insider Trade Summary
10 transactions reported
Mixed
10 txns
Insider
Blumenfeld S Morry
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Restricted Share Units | -- | -- | -- |
Holdings After Transaction:
Options — 54,318 shares (Direct);
Ordinary Shares — 155,771 shares (Direct);
Restricted Share Units — 4,680 shares (Direct)
Footnotes (1)
- These ordinary shares represent restricted share units, which will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service. These are options to acquire ordinary shares, which have fully vested as of the date hereof. These are options to acquire ordinary shares, which options will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service.
FAQ
What does Alpha Tau Medical (DRTS) director Blumenfeld S. Morry report in this Form 3?
The Form 3 shows Blumenfeld S. Morry’s initial equity holdings in Alpha Tau Medical. He reports direct ownership of ordinary shares, restricted share units, and several stock option grants, establishing his baseline beneficial ownership as a director.
What stock options does the Alpha Tau Medical (DRTS) director report owning?
He reports several option grants over Alpha Tau Medical ordinary shares, with exercise prices ranging from $2.98 to $11.50 per share. Expiration dates span from 2028 through 2036, giving him long-dated potential to acquire additional shares.
Are any of the Alpha Tau Medical (DRTS) options already vested for the director?
Yes. A footnote states that some options to acquire ordinary shares are fully vested as of the filing date. Another footnote explains that additional options will vest in full on the earlier of one year from March 9, 2026 or the next Annual General Meeting.
Does this Alpha Tau Medical (DRTS) Form 3 show any insider buying or selling?
No new market trades are indicated. The filing classifies the entries as holdings, with transaction summaries showing no buys or sells. It primarily establishes the director’s existing ownership of shares, RSUs, and options rather than reporting fresh purchases or sales.